Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, AffaMed Therap, Organon - LARVOL DELTA

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Response to Galcanezumab in a Patient with Complex Neuropsychiatric Comorbidity: A Case Report. (PubMed, J Clin Med) - "Treatment discontinuation and reintroduction were temporally associated with worsening and subsequent improvement in headache frequency, although causality cannot be established from a single uncontrolled observation. The case also highlights the potential value of coordinated neurological and psychiatric monitoring in patients with migraine and complex neuropsychiatric profiles."

Journal • Bipolar Disorder • CNS Disorders • Migraine • Mood Disorders • Obsessive-Compulsive Disorder • Pain • Psychiatry

Chronic Migraine Remission with Combination of Remote Electrical Neuromodulation (REN) and In-Clinic / Patient-Administered Sphenopalatine Ganglion (SPG) Block (PAINWeek 2026) - "Current acute treatments included rizatriptan, ubrogepant and acetaminophen with recent discontinued acute therapies including rimegepant and NSAIDS. Current preventative treatments include onabotulinumtoxinA, galcanezumab, amitriptyline, cyclobenzaprine, ondansetron and occipital nerve blocks with recent discontinued preventatives including topiramate... Patient was seen weekly for initial treatment sequence and noted near complete resolution of acute migraine symptoms after the first in-clinic SPG administration with smaller, although noticeable, levels of relief with self-administered SPG administration. Patient also noted significant, although not complete, reduction of acute pain and nausea within the first week of initiating REN. After one month of treatment, patient noted that migraine frequency reduced to one episode per week from the previous 4 to 6 episodes and was able to manage most acute episodes with acetaminophen, with rare need for other acute..."

Clinical • CNS Disorders • Depression • Migraine

Anti-CGRP Monoclonal Antibodies in Chronic Migraine: A Position Statement of the Brazilian Academy of Headache and Orofacial Pain. (PubMed, Cureus) - "The electronic survey consisted of 49 structured questions that addressed clinical experience with CM, the prevalence of comorbid medication-overuse headache (MOH), the use of anti-CGRP mAbs fremanezumab and galcanezumab as treatment options, comparative assessment, therapeutic positioning, and consensus statements. Conclusions Diagnostic delays, high treatment resistance, and significant comorbidity burden characterize CM management in Brazil. In the opinion of the surveyed specialists, anti-CGRP mAbs are perceived as effective and well tolerated, particularly in patients with MOH, and most respondents favored their earlier positioning in the treatment algorithm."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

New Migraine Guidelines Expand Treatment Options For Migraine Prevention (RTTNews) - "The guidelines discuss how preventive medicines are different from medicines used to treat a migraine attack after it starts...The new guidelines recommend atogepant, erenumab, fremanezumab, galcanezumab, and eptinezumab as first-choice medicines for preventing migraine. These medicines are given in different ways...For people with episodic migraine, meaning migraine occurring on fewer than 15 days a month, the treatments with the strongest evidence of effectiveness include atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, propranolol, topiramate, and valproate....Botox is also an option for chronic migraine."

Clinical guideline • Migraine

Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study. (PubMed, Front Neurol) - "We conducted a retrospective, single-center observational study including 453 adults with episodic or chronic migraine treated with erenumab, galcanezumab, fremanezumab, or eptinezumab between November 2018 and April 2026. In real-world clinical practice, CGRP mAbs demonstrate comparable and durable effectiveness across age groups. Subtle long-term differences between agents may emerge, particularly for multidimensional clinical improvement, supporting individualized treatment selection."

Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case. (PubMed, Dermatol Reports) - "Among CGRP inhibitors, galcanezumab has also been authorized for the treatment of episodic cluster headache...However, to the best of our knowledge, alopecia areata (AA) associated with CGRP inhibition remains undescribed in the literature. [...]."

Journal • Alopecia • CNS Disorders • Immunology • Migraine • Pain

Case Report: Anodal DLPFC-tDCS for refractory post-traumatic cognitive fatigue in the hypometabolic brain. (PubMed, Front Hum Neurosci) - "At the time of treatment, he was taking methylphenidate and galcanezumab. Home-based anodal tDCS targeting the left DLPFC was associated with clinically meaningful reductions in chronic post-mTBI cognitive fatigue and improvements in cognitive performance. This case highlights the potential utility of FDG-PET/MRI as a biomarker to guide personalized neuromodulation and supports further investigation of DLPFC-targeted tDCS for treatment-resistant post-traumatic fatigue."

Journal • CNS Disorders • Fatigue • Obstructive Sleep Apnea • Pain • Psychiatry • Vascular Neurology

Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study. (PubMed, J Ultrason) - "Additionally, a subanalysis revealed no significant differences based on the specific monoclonal antibody (erenumab, fremanezumab, or galcanezumab) or clinical response status (responders versus non-responders). Our findings suggest that treatment with anti-CGRP monoclonal antibodies is not associated with a BHI indicative of increased cerebrovascular risk. Notably, this is the first study to include galcanezumab and fremanezumab in the evaluation of cerebrovascular risk using ultrasound, highlighting TCCD ultrasonography as a practical and non-invasive tool for the assessment of cerebrovascular reactivity in migraine."

Journal • CNS Disorders • Migraine • Pain

Emgality for Migraine in Breastmilk (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Apr 2026 ➔ Apr 2028 | Trial primary completion date: Apr 2026 ➔ Apr 2028

Trial completion date • Trial primary completion date • CNS Disorders • Migraine

Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program. (PubMed, Cephalalgia) - "Adults with migraine initiating CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) were compared with initiators of onabotulinumtoxinA from January 2018 through September 2023. Several secondary, subgroup, and supportive analyses remained inconclusive for non-inferiority. Larger adequately powered comparative safety studies are needed."

Clinical • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Ischemic stroke • Migraine • Musculoskeletal Diseases • Orthopedics • Pain

Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when? (PubMed, Expert Rev Neurother) - "PACAP-targeted therapy is a promising direction whose role in cluster headache remains to be defined. The serotonergic agent psilocybin warrants closer attention, as its early therapeutic signal merits rigorous investigation despite the legal and historical barriers constraining its study."

Journal • Review • CNS Disorders • Migraine • Pain • ADCYAP1

CGRP-pathway exposure during the pre-EBP interval in spontaneous intracranial hypotension: an exploratory retrospective case series. (PubMed, BMC Neurol) - "These observations are hypothesis-generating only and report temporal associations between CGRP-pathway initiation and short-term symptom changes in a highly selected cohort with comorbid chronic migraine. They do not demonstrate efficacy for SIH and should not be interpreted as endorsing CGRP-pathway therapy as a treatment for SIH. Prospective, controlled trials with validated headache and orthostatic endpoints, stratification by migraine status, and peripheral/CSF biomarker assessments are required."

Journal • Retrospective data • CNS Disorders • Hypotension • Migraine • Pain

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence? (PubMed, Eur J Neurol) - "Data on anti-CGRP treatments for VM remain limited, and efficacy established in headache migraine cannot be straightforwardly extrapolated to VM given differences in underlying pathophysiology. There remains a risk that initial effect estimates may diminish over time, with early outcomes partially inflated by a novelty effect, expectancy, and more nuanced methodological approaches. Targeted treatment options for this common and often debilitating condition are genuinely welcomed, but the current evidence warrants careful interpretation for CGRP-related therapies."

Journal • Review • CNS Disorders • Migraine • Pain

Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience. (PubMed, Front Neurol) - "A total of 80 patients (62 chronic and 18 episodic migraine) received Erenumab, Galcanezumab, or Rimegepant. It also highlights important challenges related to treatment access and adherence. Findings should be interpreted in the context of observational design of the study, and further controlled studies are warranted."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study. (PubMed, Cephalalgia) - "We aimed to evaluate early functional outcomes in daily and school activities, as well as headache-related outcomes after initiating CGRP mAb therapy in Japanese adolescents with migraine.MethodsThis single-center retrospective cohort study included patients aged 15-17 years who received CGRP mAb therapy (galcanezumab, fremanezumab or erenumab) for migraine between May 2021 and July 2025. Safety and tolerability findings are particularly notable given the limited evidence in this age group. Further prospective controlled studies are warranted to validate these findings and to identify predictors of early functional response."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Stroke risk associated with CGRP pathway inhibitors in adults with migraine: Systematic review and meta-analysis of randomized trials (AHS 2026) - "Trials evaluated eptinezumab, erenumab, fremanezumab, and galcanezumab, with follow-up ranging from 12 to 56 weeks. Available randomized evidence does not suggest an increased risk of stroke or TIA with CGRP pathway inhibitors in adults with migraine. Although longer follow-up and real-world data are needed—particularly in patients with elevated baseline vascular risk—these findings provide reassuring cerebrovascular safety data supporting continued clinical use."

Retrospective data • Review • CNS Disorders • Migraine • Pain

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. (PubMed, Headache) - "Commercial launch was the most consistent driver of public search interest in CGRP-targeting therapies. Media exposure produced additional increases in selected cases, whereas regulatory approvals and clinical trial publications had limited measurable impact. These findings underscore the dominant role of commercial and consumer-facing communication in shaping public awareness of new migraine treatments."

Journal • CNS Disorders • Migraine • Pain

Characteristics of Migraine Patients Who Successfully Discontinued Anti-CGRP Monoclonal Antibodies: A Single-Center Retrospective Study (EAN 2026) - " The anti-CGRP mAbs administered included galcanezumab ( n = 96), erenumab ( n = 66), and fremanezumab ( n = 95). Successful discontinuation of anti-CGRP mAbs was independently associated with fewer baseline MMDs and absence of MOH. Early initiation of preventive therapy—before high frequency and medication overuse develop—may enhance the likelihood of successful treatment withdrawal, supporting a treat-to-target strategy aimed at eventual treatment graduation."

Retrospective data • CNS Disorders • Migraine

Beyond Triptans in menstrual migraine: the emerging role of CGRP-Targeted therapies. (PubMed, Expert Opin Emerg Drugs) - "Among available options, gepants offer the greatest potential due to their flexibility for both acute and short-term preventive use. Future research should focus on time-specific treatment strategies and a broader understanding of the underlying biology, including the role of additional neuropeptides."

Journal • Review • CNS Disorders • Migraine • Pain

Digital milestones and public interest in CGRP-targeting migraine therapies: An infodemiology study in the United States (AHS 2026) - "Seven FDA-approved preventive therapies were analyzed: erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, and ubrogepant. In the United States, commercial launches and targeted media exposure are the dominant drivers of public interest in CGRP-targeting therapies, while regulatory approvals and trial publications have limited impact. These findings highlight outsized influence of market entry and consumer-facing media on awareness of CGRP-targeting therapies, underscoring opportunities to strengthen communication around scientific and regulatory milestones. Public search interest in CGRP-therapies in the United States (2017–2025)."

CNS Disorders • Migraine • Pain

CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis. (PubMed, Med Sci (Basel)) - "CGRP monoclonal antibodies show a consistent direction of benefit for vestibular symptoms, migraine days, and dizziness handicap in observational VM studies, with a favorable safety profile. However, the absence of RCTs, small samples, lack of control groups, and heterogeneity preclude definitive conclusions. This synthesis highlights a critical evidence gap. Adequately powered, double-blind, placebo-controlled RCTs of CGRP-targeting therapies (both monoclonal antibodies and gepants) are urgently needed."

Clinical • Journal • Review • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo